What Is DSO M&A and How Do Dental Mergers and Acquisitions Work?

Every dentist knows someone who sold to a DSO, and if you've talked to more than one of them, you've probably noticed their stories don't match. Some doctors love where they landed. Some are still deciding how they feel about it five years later. 

That gap usually comes down to one thing: doctors go into a deal without a clear picture of what a DSO transaction actually is, how it's structured, or what changes once the ink is dry. 

DSO M&A (mergers and acquisitions) is the process by which a DSO acquires or partners with an existing dental practice. It's become one of the primary growth paths in dentistry over the last 15 years, and for good reason: it gives doctors access to capital, infrastructure, and resources that are hard to build alone, and it gives groups a way to scale quality care across more communities. 

This guide walks through how these deals are typically structured, what diligence actually looks like, what drives a practice's valuation, and what actually changes for the practice, the team, and the patients once the deal closes. 

One quick note before going further: nothing here is investment, legal, or tax advice. Every deal and every state has its own nuances. This is meant to help you understand the mechanics well enough to ask better questions. 

Common DSO deal structures: full acquisition, partnership, and equity rollover 

Not every DSO deal looks the same, and the differences matter far more than most doctors realize going in. 

At the simplest level, a full acquisition means the DSO buys the practice outright. The doctor may stay on as a clinician, but ownership of the business transfers entirely to the DSO. 

A partnership model looks different. Instead of a straight sale, the doctor retains some ownership stake in the practice or the larger organization, with shared decision-making and mutual accountability built into the arrangement. Some groups brand themselves specifically around this distinction, positioning themselves as a partner rather than a buyer, though the underlying legal and financial mechanics still need to be evaluated deal by deal, since "partnership" language doesn't guarantee any particular structure. 

Then there's the equity rollover, which is where things get genuinely complicated. Rollover equity means a portion of the doctor's proceeds isn't paid out in cash. It's reinvested into equity in the parent company, a joint venture, or sometimes a synthetic equity structure designed to mimic ownership without full legal ownership. Some deals blend multiple types of rollover equity in the same transaction. 

This is, hands down, the part of deal structure most doctors misunderstand: how rollover equity is structured, when it vests, what it's actually worth, and what happens to it at a future liquidity event. If you only research one part of a term sheet before signing, make it this one. 

What happens during diligence: financials, clinical quality, and systems 

Diligence is where a DSO tries to understand the practice well enough to make a fair offer, and where a lot of deals quietly fall apart. 

On the financial side, the DSO is looking at a couple of years of profit-and-loss statements, practice management reports, lease agreements, tax returns, staff rosters, payor mix, and procedure mix. It sounds basic, but it's consistently the part of the process that trips doctors up, simply because most practices haven't kept clean, consistent financial records for years at a time. 

Accuracy matters most here. A practice's earnings, typically measured as EBITDA, are the foundation for its valuation. But EBITDA can be shaped, intentionally or not, by how a practice books expenses, defers income, or treats owner compensation. It's a real number that requires real records. Practices that manage their own books loosely, or make aggressive adjustments to reduce taxable income, often create problems for themselves later, because those same adjustments make it much harder for a buyer to trust the number being presented. 

Diligence also isn't purely financial. A serious DSO is evaluating clinical quality, systems and technology in use, team structure, and how the practice actually runs day to day, because all of that becomes the DSO's responsibility the moment the deal closes. 

The single biggest way doctors slow this process down is by not having their information organized. Pulling together a couple of years of financials, lease documents, and a staff roster ahead of time can take weeks, sometimes months, off the total deal timeline. 

Valuation basics: what drives a practice's multiple 

Here's the myth that needs busting first: a higher multiple does not automatically mean a better deal. 

The multiple is one input in the valuation, applied to EBITDA to arrive at a headline number. But the multiple gets outsized attention relative to its actual importance. What matters more is how the deal is structured around that number: how much is paid in cash versus rollover equity, when that equity vests or pays out, what the ongoing compensation model looks like, and what obligations come with it. 

A practice with a slightly lower multiple but a stronger, clearer cash-at-close structure and a fair, well-understood equity component can be a meaningfully better outcome than a practice that chased the highest headline multiple and later found the structure behind it far less favorable. 

Valuation is also shaped by the specific characteristics of the practice, procedure mix, payor mix, staff stability, facility condition, and local market dynamics, as well as the buyer's own model and how it prices risk. There's no universal formula. Two practices with similar EBITDA can land at very different valuations depending on these variables. 

Integration after close: converting systems, standardizing workflows, and retaining staff 

This is the myth that costs doctors and their teams the most stress: the belief that nothing will change after the deal closes. 

Something always changes. There is no version of a DSO transaction where the business operates exactly as it did the day before. But the problem isn't that things change. The problem is when doctors aren't told what's changing, so their teams find out the hard way and assume the worst. 

The way to prevent that is straightforward, if not always easy: get specific about what changes, how, when, and why, and communicate that clearly, early, and consistently. In a well-run integration, the team that’ll support the practice long-term is introduced well before closing, and they should already understand the doctor's goals and the practice's specific situation by the time the deal closes, so there's no jarring handoff from "the deal people" to "the operations people." 

The practical mechanics of integration typically include enrolling the team in new benefits, converting to standardized systems for scheduling, payment processing, and reporting, and a financial reconciliation period, since revenue and vendor relationships generally can't be redirected until the deal is legally final. 

The people side of integration matters just as much as the systems side. Every team member reacts differently to a change in ownership, often based on assumptions about "corporate dentistry" that have nothing to do with the actual deal. Hygienists worry about new clinical protocols. Dental assistants worry about their hours or scope changing. Front desk staff worry about new layers of reporting or a new boss. Associates worry about compensation changes or corporate oversight of clinical decisions. These fears are common, predictable, and manageable, if the practice and the DSO get ahead of them with honest, role-specific communication before the reactions have a chance to set in. 

Practices with owners who are collaborative and responsive during this window tend to have smoother integrations. Owners who resist the process before closing are often signaling how they'll behave as a partner afterward, which is exactly why a well-run integration team pays close attention to that dynamic long before day one. 

Why technology integration is often the hardest part of a DSO deal 

Of everything that changes when a practice joins a DSO, the technology stack is usually where the risk of a bumpy transition is highest. 

Every practice comes in with its own practice management system, scheduling habits, payment processing setup, and way of tracking KPIs. Multiply that across dozens or hundreds of acquired practices, and a DSO can end up managing a genuinely fragmented mess of platforms, none of which talk to each other cleanly. That fragmentation makes it harder to get an accurate read on how a practice, or an entire group, is actually performing, and it slows down every future integration that follows. 

This is exactly why the technology decisions a DSO makes, and the partner it chooses for its practice management platform, matter well beyond any single transaction. For a DSO managing acquisitions on an ongoing basis, that turns technology integration from the hardest part of the deal into one of the more predictable parts, and gives leadership a clear, consistent view across every practice in the group from day one. 

The bottom line 

DSO M&A isn't a single moment. It's a process with distinct phases, each with its own risks and its own way of going sideways if it's rushed or poorly communicated. Understanding deal structure, diligence, valuation, and integration before you're in the middle of a transaction is the best way to go into it with clear eyes, ask the right questions, and know what you're actually signing up for. 

If you're a doctor weighing this decision, the one question worth insisting on a straight answer to is simple: what, specifically, changes about my business, and when? Get that in writing, understand it fully, and you'll be in a much stronger position than the doctors whose deal stories don't match anyone else's.